[HTML][HTML] A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev

J Fang, S Kubota, B Yang, N Zhou, H Zhang… - Virology, 2004 - Elsevier
J Fang, S Kubota, B Yang, N Zhou, H Zhang, R Godbout, RJ Pomerantz
Virology, 2004Elsevier
HIV-1 Rev escorts unspliced viral mRNAs out of the nucleus of infected cells, which allows
formation of infectious HIV-1 virions. We have identified a putative DEAD box (Asp–Glu–Ala–
Asp) RNA helicase, DDX1, as a cellular co-factor of Rev, through yeast and mammalian two-
hybrid systems using the N-terminal motif of Rev as “bait”. DDX1 is not a functional homolog
of HIV-1 Rev, but down-regulation of DDX1 resulted in an alternative splicing pattern of Rev-
responsive element (RRE)-containing mRNA, and attenuation of Gag p24 antigen …
HIV-1 Rev escorts unspliced viral mRNAs out of the nucleus of infected cells, which allows formation of infectious HIV-1 virions. We have identified a putative DEAD box (Asp–Glu–Ala–Asp) RNA helicase, DDX1, as a cellular co-factor of Rev, through yeast and mammalian two-hybrid systems using the N-terminal motif of Rev as “bait”. DDX1 is not a functional homolog of HIV-1 Rev, but down-regulation of DDX1 resulted in an alternative splicing pattern of Rev-responsive element (RRE)-containing mRNA, and attenuation of Gag p24 antigen production from HLfb rev(−) cells rescued by exogenous Rev. Co-transfection of a DDX1 expression vector with HIV-1 significantly increased viral production. DDX1 binding to Rev, as well as to the RRE, strongly suggest that DDX1 affects Rev function through the Rev–RRE axis. Moreover, down-regulation of DDX1 altered the steady state subcellular distribution of Rev, from nuclear/nucleolar to cytoplasmic dominance. These findings indicate that DDX1 is a critical cellular co-factor for Rev function, which maintains the proper subcellular distribution of this lentiviral regulatory protein. Therefore, alterations in DDX1–Rev interactions could induce HIV-1 persistence and targeting DDX1 may lead to rationally designed and novel anti-HIV-1 strategies and therapeutics.
Elsevier